ClinicalTrials.gg
CompletedNCT04857320Updated Oct 23, 2023Results posted

Transdermal Insulin Response In Healthy Volunteers

An Early Phase 1 interventional study of Human insulin in Pharmacodynamic Response to Small Doses of Insulin, sponsored by Transdermal Delivery Solutions Corp. Completed at 1 site in United States. Open to male participants aged 20 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-10-23.

Sponsored by Transdermal Delivery Solutions Corp · Early Phase 1, Interventional, and Device feasibility

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Early Phase 1
Study type
Interventional
Enrollment
7
Allocation
Not applicable
Ages
20 Years to 60 Years
Sex
Male
01

Study summary

Bio-fermentation produced Human insulin is available without prescription in the U.S. This study is a physician-initiated trial of a formula enabling transdermal delivery of human insulin.

Read the detailed description

The primary objective of the study is to determine the amount of lowering serum glucose as a function of dose of a topically applied formulation of Human Insulin administered by syringe measurement to adult Healthy Volunteer subjects as compared to no treatment. A 5-day period of daily blood sugar monitoring by means of wearable Continuous Glucose Monitor and insulin dosing for 3 days then monitoring for at least 3 days following will form the baseline and experimental data for each subject.

The secondary objective is to evaluate the tolerability and local and systemic effects of transdermal Human Insulin if any.

02

Conditions studied

  • Pharmacodynamic Response to Small Doses of Insulin
03

In context

Lead sponsor

Transdermal Delivery Solutions Corp is the lead sponsor of 5 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 60 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. The subject has a serum protein of less than 6.
  2. The subject is willing and able to read, understand the Subject Information Sheet and provide written .
  3. The subject has a (BMI) within 18-50 kg/m2.
  4. The subject is in otherwise good health as determined by medical history and physical examination.
  5. The subject is a non-smoker.
  6. The subject must agree to continue with daily serum glucose testing by means of a wearable blood glucose for the pharmacokinetic assessments.
  7. The subject is willing and able to comply with all testing and requirements defined in the protocol.
  8. The subject is willing and able to return to the study site for all visits.

Exclusion criteria

Exclusion Criteria:

  1. The subject has any relevant deviations from normal other than blood glucose in physical examination, (ECG), or clinical laboratory tests, as evaluated by the investigator.
  2. The subject has had a illness within 30 days preceding entry into this study.
  3. The subject has a history of significant neurological, hepatic, renal, endocrine, cardiovascular, gastrointestinal, pulmonary, or metabolic disease.
  4. The subject has a known allergy or history of to Human Insulin or similar modified Insulin compounds.
  5. The subject has used any prescription medication that may interfere with the evaluation of study medication.
  6. The subject has donated or lost a significant volume of blood (>450 mL) within four (4) weeks of the study, and their concentration and haematocrit have not returned to within 5% of normal.
  7. The subject has a history of substance abuse or a current positive urine drug screen or urine alcohol test.
  8. Alcohol consumption greater than community norms (i.e. more than 21 standard drinks per week for males).
  9. Subjects who have received an drug or have used an investigational device in the 30 days prior to study entry
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Early Phase 1
Primary purpose
Device feasibility
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
7 participants (actual)

Study arms

  • Experimental
    Main Experimental

    Each subject will receive doses applied to the skin of 0.075 IUs / Kilogram Body Weight, 0.1 IUs/Kilogram Body Weight and 0.15 IUs /Kilogram Body Weight

    Combination Product: Human insulin

Interventions

  • Combination productHuman insulin

    Human Insulin from recombinant source delivered in a solution capable of enabling transdermal delivery formulated at 100 IU/mL of delivery vehicle.

06

What researchers measure

Primary outcomes

  1. Postprandial Serum Glucose in mg/dL as a Response to Small Doses (0.075 to 0.15 IUs/Kg) Human Insulin Averaged Per Subject

    An Average Postprandial serum glucose measured by the Continuous Glucose Monitor as a response to a single dose of Human Insulin averaged (Mean) for each Subject. Data is reported in mg/dL. The Average reported was a comparison from Baseline (Day 1) and up to 3.5 hours following each dose (assessed at Day 1 - Baseline, Day 2 - Dose 1, Day 3 - Dose 2, and Day 4 - Dose 3)"

    Time frame: Pre-dose Baseline & a Mean of readings over 3.5 hours

  2. Daily Average Serum Glucose Measured in mg/dL as a Response to Small Doses (0.075 to 0.15 IUs/Kg) Human Insulin

    Daily average serum glucose measured by the Continuous Glucose Monitor in measured in mg/dL as a response to a single dose of Human Insulin and reported by the Freestyle 14-day software. Data was collected 4 times an hour throughout the test period and across doses. The prandial segments were included in this average. Data is reported in mg/dL by subject.

    Time frame: 72 hours

Secondary outcomes

  1. OECD Acute Dermal Irritation/Corrosion Score According to to the Organisation for Economic Co-operation and Development (OECD) Guideline for Testing of Chemicals No. 404

    The skin at the application site will be assessed at each Clinic Visit by the investigator and/or Study Nurse. Any dermal irritation will be scored according to to the Organisation for Economic Co-operation and Development (OECD) Guideline for Testing of Chemicals No. 404, adopted 17th July, 1992: "Acute Dermal Irritation/Corrosion" and any score of 0 or greater will be reported. The Guideline is a scale of from Zero (No erythema or edema), 1: Very slight, 2: Well-defined erythema/Slight edema (edges of area well-defined by definite raising), 3: Moderate to severe erythema/Moderate edema (raised approximately 1 mm) to 4: Severe erythema (beet redness) to eschar formation preventing grading / Severe edema (raised more than 1 mm, extending beyond area of exposure). The higher the score the worse the erythema or edema, so a score of 0 is very good and a score of 4 is very bad.

    Time frame: 20 Days

07

Results

Posted Oct 10, 2023

Participant flow

Subjects ("Ss") were recruited by word-of-mouth and attended a study orientation where the study participation expectations were discussed and the informed consent forms provided. Ss underwent a health screening to ascertain healthy, non diabetic status.

Participant flow — Overall Study
MilestoneMain Experimental
Started7
Completed5
Not completed2

Outcome measures

PrimaryPostprandial Serum Glucose in mg/dL as a Response to Small Doses (0.075 to 0.15 IUs/Kg) Human Insulin Averaged Per Subject

An Average Postprandial serum glucose measured by the Continuous Glucose Monitor as a response to a single dose of Human Insulin averaged (Mean) for each Subject. Data is reported in mg/dL. The Average reported was a comparison from Baseline (Day 1) and up to 3.5 hours following each dose (assessed at Day 1 - Baseline, Day 2 - Dose 1, Day 3 - Dose 2, and Day 4 - Dose 3)"

Time frame:
Pre-dose Baseline & a Mean of readings over 3.5 hours
Reported as:
Mean · mg/dL
Postprandial Serum Glucose in mg/dL as a Response to Small Doses (0.075 to 0.15 IUs/Kg) Human Insulin Averaged Per Subject
mg/dLDose 1Dose 2Dose 3
Postprandial Serum Glucose in mg/dL as a Response to Small Doses (0.075 to 0.15 IUs/Kg) Human Insulin Averaged Per Subject3.8 (-3 to 6)-1.8 (-5 to 1)7 (-3 to 9)
Statistical analysis
  • Dose 1 vs Dose 2 vs Dose 3 · ANOVA · p = 0.000016Degrees of Freedom = 5
PrimaryDaily Average Serum Glucose Measured in mg/dL as a Response to Small Doses (0.075 to 0.15 IUs/Kg) Human Insulin

Daily average serum glucose measured by the Continuous Glucose Monitor in measured in mg/dL as a response to a single dose of Human Insulin and reported by the Freestyle 14-day software. Data was collected 4 times an hour throughout the test period and across doses. The prandial segments were included in this average. Data is reported in mg/dL by subject.

Time frame:
72 hours
Reported as:
Mean · mg/dL Serum Glucose
Daily Average Serum Glucose Measured in mg/dL as a Response to Small Doses (0.075 to 0.15 IUs/Kg) Human Insulin
mg/dL Serum GlucoseSubject 1Subject 2Subject 4Subject 5Subject 6
Daily Average Serum Glucose Measured in mg/dL as a Response to Small Doses (0.075 to 0.15 IUs/Kg) Human Insulin95 (94 to 95)99 (98 to 101)85 (85 to 85)89 (87 to 93)103 (101 to 105)
Statistical analysis
  • Subject 1 vs Subject 2 vs Subject 4 vs Subject 5 vs Subject 6 · t-test, 1 sided · p = 0Degrees of Freedom = 3
  • Subject 2 · t-test, 1 sided · p = 0.000003
  • Subject 4 · t-test, 1 sided · p = 0.000002Degrees of Freedom = 3
  • Subject 5 · t-test, 1 sided · p = 0.000035Degrees of Freedom = 3
  • Subject 6 · t-test, 1 sided · p = 0.000004Degrees of Freedom = 3
SecondaryOECD Acute Dermal Irritation/Corrosion Score According to to the Organisation for Economic Co-operation and Development (OECD) Guideline for Testing of Chemicals No. 404

The skin at the application site will be assessed at each Clinic Visit by the investigator and/or Study Nurse. Any dermal irritation will be scored according to to the Organisation for Economic Co-operation and Development (OECD) Guideline for Testing of Chemicals No. 404, adopted 17th July, 1992: "Acute Dermal Irritation/Corrosion" and any score of 0 or greater will be reported. The Guideline is a scale of from Zero (No erythema or edema), 1: Very slight, 2: Well-defined erythema/Slight edema (edges of area well-defined by definite raising), 3: Moderate to severe erythema/Moderate edema (raised approximately 1 mm) to 4: Severe erythema (beet redness) to eschar formation preventing grading / Severe edema (raised more than 1 mm, extending beyond area of exposure). The higher the score the worse the erythema or edema, so a score of 0 is very good and a score of 4 is very bad.

Time frame:
20 Days
Reported as:
Median · units on a scale
OECD Acute Dermal Irritation/Corrosion Score According to to the Organisation for Economic Co-operation and Development (OECD) Guideline for Testing of Chemicals No. 404
units on a scaleMain Experimental
OECD Acute Dermal Irritation/Corrosion Score According to to the Organisation for Economic Co-operation and Development (OECD) Guideline for Testing of Chemicals No. 4040 (0 to 0)
Statistical analysis
  • Main Experimental · ANOVA · p = 0

Adverse events

Collected over 21 Days. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Main Experimental0/7 (0%)0/7 (0%)0/7 (0%)

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Main Experimental
<=18 years0
Between 18 and 65 years6
>=65 years1
Sex: Female, Male
Sex: Female, Male(Participants)Main Experimental
Female0
Male7
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Main Experimental
American Indian or Alaska Native0
Asian1
Native Hawaiian or Other Pacific Islander1
Black or African American0
White5
More than one race0
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(participants)Main Experimental
United States7
Average Untreated Serum Glucose
Average Untreated Serum Glucose(mg/dL)Main Experimental
Mean96.4 (87 to 103)
08

Study locations

1 site
  • Langford Research Institute
    Palm Beach Gardens, Florida 33410, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2021 to primary completion in Nov 2021, 8 months.

Results were first posted in Oct 2023, 1 year 10 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 21, 2021
First posted
Apr 23, 2021
StartActual
Mar 12, 2021
Primary completionActual
Nov 15, 2021
CompletionActual
Nov 15, 2021
Results first posted
Oct 10, 2023
Last update
Oct 23, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 23, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04857320
Lead sponsor
Transdermal Delivery Solutions Corp
Collaborators
Langford Research Institute, Inc.
Responsible party
Sponsor
First posted
Apr 23, 2021
Start date
Mar 12, 2021
Primary completion
Nov 15, 2021
Completion
Nov 15, 2021
Results posted
Oct 10, 2023
Last update
Oct 23, 2023

Study contacts

William D. Kirsh, D.O., M.P.H.
principal investigator · Langford Research Institute

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Insulin, Regular, Human

Start the discussion